Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 3, pp 401–408 | Cite as

A population-based study of transdermal fentanyl initiation in Australian clinical practice

  • Natasa GisevEmail author
  • Sallie-Anne Pearson
  • Briony Larance
  • Sarah Larney
  • Bianca Blanch
  • Louisa Degenhardt
Pharmacoepidemiology and Prescription

Abstract

Purpose

Although guidelines caution against initiation of transdermal (TD) fentanyl among those who are opioid naïve, there is concern that not all people receive adequate prior opioid exposure. This study examined the percentage of people who are opioid naïve at the time of TD fentanyl initiation in Australia; strengths initiated; and characteristics associated with being opioid naïve.

Methods

This is a national retrospective cohort study derived from a 10% sample of Pharmaceutical Benefits Scheme concessional beneficiaries initiating TD fentanyl between 29 September 2009–31 December 2013. Individuals were deemed opioid naïve if they had no opioid dispensings in the previous 90 days. Logistic regression was used to determine characteristics associated with being opioid naïve, including socio-demographics, likely comorbidities and previous analgesic use.

Results

A total of 13,166 people initiated TD fentanyl; 60.4% were female and 76.2% were aged ≥ 65 years. Three in ten (30.4%) were opioid naïve and 63.2% initiated the 12 mcg/h patch. Those who were opioid naïve were more likely to be female (adjusted odds ratio (aOR) 1.35; 95% CI 1.25–1.46), older (aOR 1.85; 95% CI 1.54–2.28 for those ≥ 85 years) and previously dispensed medicines for dementia (aOR 1.37; 95% CI 1.04–1.80). People previously dispensed medicines for cancer were less likely to be opioid naïve (aOR 0.57; 95% CI 0.48–0.67).

Conclusions

Three in ten Australians initiating TD fentanyl are opioid naïve. Our findings suggest that specific patient sub-populations already at increased risk of opioid-related adverse events are not receiving prior opioid treatment before initiation, highlighting the need for greater adherence to current treatment guidelines.

Keywords

(MeSH): Analgesics Drug utilization Fentanyl Opioids Pain Pharmacoepidemiology 

Notes

Acknowledgments

We wish to acknowledge the data custodian, the Department of Human Services, for providing access to the data used in this study. We are also grateful for Melisa Litchfield’s assistance with the initial coding and preparation of the dataset for analysis.

Author contributions

NG conceived the idea, undertook the analysis and wrote the first draft of the manuscript. All other authors (SAP, LD, BL, SL, BB) were involved in the conceptualisation of the study from which this data was drawn, assisted in data interpretation and critically revised drafts of the manuscript. All authors approved the final manuscript prior to submission.

Funding

This research is supported, in part, by a National Health and Medical Research Council Health (NHMRC) Centre of Research Excellence in Medicines and Ageing (CREMA) (ID: 1060407), and by funding from an NHMRC grant (#1005668). NG, LD and BL are supported by NHMRC Research Fellowships (#1091878, #1041472, #1073858). The National Drug and Alcohol Research Centre at UNSW Australia is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund.

Compliance with ethical standards

Competing interests

LD and BL have received untied educational grants from Reckitt Benckiser, Mundipharma and Seqirus to conduct post-marketing surveillance of new opioid medications in Australia. LD, BL and SL have also received untied educational grants from Indivior. No company had any knowledge or involvement in this study.

Supplementary material

228_2018_2588_MOESM1_ESM.docx (21 kb)
ESM 1 (DOCX 21 kb)

References

  1. 1.
    Schug SA, Ting S (2017) Fentanyl formulations in the management of pain: an update. Drugs 77:747–763CrossRefGoogle Scholar
  2. 2.
    International Narcotics Control Board (2015) Narcotic drugs estimated world requirements for 2015 - statistics for 2013. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2014/ND_TR_2014_2_Comments_EN.pdf. Accessed 23 October 2015
  3. 3.
    Greenall J, Koczmara C, Cheng R, Hyland S (2008) Safety issues with fentanyl patches require pharmaceutical care. Can J Hosp Pharm 61:57–59Google Scholar
  4. 4.
    US Food & Drug Administration (2013) Information for healthcare professionals: fentanyl transdermal system (marketed as Duragesic and generics) - 12/21/2007 update. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084307.htm. Accessed 28 July 2017
  5. 5.
    Garbe E, Jobski K, Schmid U (2012) Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 21:191–198CrossRefGoogle Scholar
  6. 6.
    NSW Therapeutic Advisory Group Inc (2016) Opioid skin patches are high risk medicines. http://www.ciap.health.nsw.gov.au/nswtag/documents/publications/practical-guidance/opioid-skin-patches-alert-september-2016.pdf. Accessed 28 July 2017
  7. 7.
    Therapeutic Guidelines (2018) eTG complete: analgesic. Therapeutic Guidelines Ltd, MelbourneGoogle Scholar
  8. 8.
    Currow DC, Phillips J, Clark K (2016) Using opioids in general practice for chronic non-cancer pain: an overview of current evidence. Med J Aust 204:305–309CrossRefGoogle Scholar
  9. 9.
    Tournebize J, Gibaja V, Muszczak A, Kahn J-P (2016) Are physicians safely prescribing opioids for chronic noncancer pain? A systematic review of current evidence. Pain Pract 16:370–383CrossRefGoogle Scholar
  10. 10.
    Breekveldt-Postma NS, Penning-van Beest FJA, Herings RMC (2005) Utilisation pattern of fentanyl transdermal system in the Netherlands. Pharmacoepidemiol Drug Saf 14:129–134CrossRefGoogle Scholar
  11. 11.
    Friesen KJ, Woelk C, Bugden S (2016) Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches. CMAJ 188:648–653CrossRefGoogle Scholar
  12. 12.
    Pimentel CB, Gurwitz JH, Tjia J, Hume AL, Lapane KL (2016) New initiation of long-acting opioids in long-stay nursing home residents. JAGS 64:1772–1778CrossRefGoogle Scholar
  13. 13.
    Australian Government Department of Health (2017) The pharmaceutical benefits scheme. http://www.pbs.gov.au/pbs/search?term=fentanyl. Accessed 28 July 2017
  14. 14.
    Campbell G, Nielsen S, Bruno R, Lintzeris N, Cohen M, Hall W, Larance B, Mattick RP, Degenhardt L (2015) The pain and opioids IN treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. Pain 156:231–242CrossRefGoogle Scholar
  15. 15.
    Gisev N, Larance B, Cama E, Nielsen S, Roxburgh A, Bruno R, Degenhardt L (2017) A nationwide study of the extent and factors associated with fentanyl use in Australia. Res Social Adm Pharm 14:303–308CrossRefGoogle Scholar
  16. 16.
    Drug Utilisation Sub-Committee (2014) Opioid analgesics: overview. Australian Government Department of Health, CanberraGoogle Scholar
  17. 17.
    Gadzhanova S, Roughead EE, Pont LG (2015) Safety of opioid patch initiation in Australian residential aged care. Med J Aust 203:298CrossRefGoogle Scholar
  18. 18.
    Gisev N, Pearson S, Blanch B, Larance B, Dobbins T, Larney S, Degenhardt L (2016) Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. Br J Clin Pharmacol 82:1123–1133CrossRefGoogle Scholar
  19. 19.
    Degenhardt L, Blanch B, Gisev N, Larance B, Pearson S (2015) The POPPY research programme protocol: investigating opioid utilisation, costs and patterns of extramedical use in Australia. BMJ Open 5:e007030.  https://doi.org/10.1136/bmjopen-2014-007030 CrossRefGoogle Scholar
  20. 20.
    Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, Segrave A, Pearson S-A (2015) The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes 8:634.  https://doi.org/10.1186/s13104-13015-11616-13108 CrossRefGoogle Scholar
  21. 21.
    Department of Health and Ageing (2013) Trends in and drivers of pharmaceutical benefits scheme expenditure. http://www.pbs.gov.au/statistics/asm/2010/australian-statistics-on-medicine-2010.pdf. Accessed 27 January 2016
  22. 22.
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress H-G, Langford R, Likar R, Raffa RB, Sacerdote P (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287–313CrossRefGoogle Scholar
  23. 23.
    Australian Bureau of Statistics (2007) 1216.0.15.003 - Australian Standard Geographical Classification (ASGC) Remoteness Area Correspondences, 2006. http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1216.0.15.003Main+Features12006?. OpenDocument. Accessed 31 August 2014
  24. 24.
    Pink B (2008) Information paper: an introduction to socio-economic indexes for areas (SEIFA). In: Australian Bureau of Statistics. CanberraGoogle Scholar
  25. 25.
    Lu CY, Barratt J, Vitry A, Roughead E (2011) Charlson and Rx-risk comorbidity indices were predictive of mortality in the Australian health care setting. J Clin Epidemiol 64:223–228CrossRefGoogle Scholar
  26. 26.
    Blyth FM, March LM, Brnabic AJM, Jorm LR, Williamson M, Cousins MJ (2001) Chronic pain in Australia: a prevalence study. Pain 89:127–134CrossRefGoogle Scholar
  27. 27.
    Karanges EA, Blanch B, Buckley NA, Pearson S (2016) Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol 82:255–267CrossRefGoogle Scholar
  28. 28.
    National Opioid Use Guideline Group (2010) Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. http://nationalpaincentre.mcmaster.ca/opioid/. Accessed 1 August 2017
  29. 29.
    Dowell D, Haegerich TM, Chou R (2016) CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Morb Mortal Wkly Rep 65:1–49Google Scholar
  30. 30.
    Roxburgh A, Hall WD, Dobbins T, Gisev N, Burns L, Pearson S, Degenhardt L (2017) Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend 179:291–298CrossRefGoogle Scholar
  31. 31.
    Dosa DM, Dore DD, Mor V, Teno JM (2009) Frequency of long-acting opioid analgesic initiation in opioid-naïve nursing home residents. J Pain Symptom Manag 38:515–521CrossRefGoogle Scholar
  32. 32.
    Achterberg WP, Pieper MJC, van Dalen-Kok AH, de Waal MWM, Husebo BS, Lautenbacher S, Kunz M, Scherder EJA, Corbett A (2013) Pain management in patients with dementia. Clin Interv Aging 8:1471–1482CrossRefGoogle Scholar
  33. 33.
    Bowie MW, Slattum PW (2007) Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother 5:263–303CrossRefGoogle Scholar
  34. 34.
    Gisev N, Pearson SA, Karanges EA, Larance B, Buckley NA, Larney S, Dobbins T, Blanch B, Degenhardt L (2017) To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia? Pharmacoepidemiol Drug Saf 27:550–555CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.National Drug and Alcohol Research CentreUNSW SydneySydneyAustralia
  2. 2.Centre for Big Data Research in HealthUNSW SydneySydneyAustralia
  3. 3.The Centenary InstituteSydneyAustralia

Personalised recommendations